UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Raises Stake in Humana Inc. $HUM

Key Points

• UBS AM increased its holdings in Humana Inc. by 16.2% in the first quarter, owning a total of 1,136,538 shares worth approximately $300.7 million.
• A number of other institutional investors also boosted their positions, with Woodline Partners LP and Empowered Funds LLC increasing their stakes by 460% and 814.8%, respectively.
• Humana's stock has a current average target price of $289.24 and a consensus rating of "Hold" from analysts, with price targets ranging from $260 to $315.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Humana Inc. (NYSE:HUM - Free Report) by 16.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,136,538 shares of the insurance provider's stock after purchasing an additional 158,528 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.94% of Humana worth $300,728,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after buying an additional 1,143,662 shares during the period. Dodge & Cox boosted its holdings in shares of Humana by 5.5% in the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock valued at $2,845,830,000 after purchasing an additional 557,175 shares during the period. Pzena Investment Management LLC grew its stake in Humana by 6.1% in the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock worth $1,013,133,000 after purchasing an additional 219,541 shares in the last quarter. Davis Selected Advisers increased its holdings in Humana by 3.3% during the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider's stock worth $616,873,000 after purchasing an additional 74,434 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC raised its position in Humana by 1.6% during the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider's stock valued at $327,293,000 after purchasing an additional 19,613 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on HUM shares. Morgan Stanley dropped their price target on Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Robert W. Baird dropped their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Sanford C. Bernstein boosted their price target on shares of Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Truist Financial cut their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Seven investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the stock. According to MarketBeat.com, Humana has a consensus rating of "Hold" and a consensus price target of $289.24.

Humana Stock Down 0.8%

HUM stock traded down $2.36 on Friday, hitting $276.36. 1,138,341 shares of the company's stock were exchanged, compared to its average volume of 1,648,760. The firm has a 50 day moving average price of $265.34 and a two-hundred day moving average price of $257.18. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $325.75. The stock has a market cap of $33.24 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 1.64 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business's revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the company earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. Humana's dividend payout ratio (DPR) is currently 27.17%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.